Learn about FEIBA

Prompt and effective treatment of joint bleeds is essential to prevent lasting complications while effective management over the long term can help prevent joint and muscle damage.1,2 Factor VIII and Factor IX inhibitor patients present a distinct clinical challenge. Patients with inhibitors are at greater risk for complications that can disrupt their lives and are more difficult to manage.3,4

FEIBA provides long-acting protection to patients

Explore this section to discover how incorporating FEIBA into your inhibitor management strategy may help bring about extended freedom for your patients.

FEIBA is a unique composition of coagulation factors. Learn about the unique mode of action that allows FEIBA to target multiple sites within the coagulation system to help facilitate haemostatis.5,6

FEIBA is formulated with multiple active components that quickly induce thrombin generation (15 to 30 minutes in an in vitro assay) and help to maintain the coagulation process.5,6

The efficacy of FEIBA in on-demand therapy has been established in clinical studies and across multiple bleeds. In a prospective study, FEIBA demonstrated up to 93% efficacy in stopping bleeds within 72 hours.7 In a separate prospective study, a single FEIBA infusion was rated effective in 80.9% of bleeds within six hours and 95.2% of bleeds within 24 hours.8

Several studies have demonstrated that FEIBA prophylaxis can reduce bleed frequency and provide orthopaedic benefit.9,10

Every bleed is different and patients may respond differently to different therapies.8,11 It can also be difficult to predict a patient's response to bypass therapy.8,12 To help improve outcomes, make FEIBA an integral part of your inhibitor therapy regimen.13

FEIBA has a long history of successful use—more than 30 years—and is licensed in more than 60 countries.14

Access important articles related to the management of haemophilia patients with inhibitors.

Important Safety Information

FEIBA must not be used in the following situations if therapeutic alternatives to FEIBA are available:

  • Hypersensitivity to the product or any of the components.
  • Disseminated Intravascular Coagulation (DIC).
  • Acute thrombosis or embolism (including myocardial infarction).

Thrombotic and thromboembolic events, including disseminated intravascular coagulation (DIC), venous thrombosis, pulmonary embolism, myocardial infarction, and stroke have occurred in the course of treatment with FEIBA, particularly after administration of doses above the maximum daily dose and/or prolonged application or in patients with other risk factors for thromboembolic events.
As with any intravenously administered plasma product, allergic type hypersensitivity reactions may occur; patients should be informed of the early signs of hypersensitivity reactions. When medicines prepared from human blood or plasma are administered, the possibility of passing on infection cannot be totally excluded. This also applies to any unknown or emerging viruses or other types of infections.
Administration of FEIBA to patients with inhibitors may result in an initial anamnestic rise in inhibitor levels. Upon continued administration of FEIBA, inhibitors may decrease over time. Clinical and published data suggest that the efficacy of FEIBA is not reduced.


  1. 1. Dietrich SL. The treatment of hemophilia bleeding with limited resources. Treatment of Hemophilia. 2004:1:1-10.
  2. 2. World Federation of Hemophilia. Guidelines for the management of hemophilia. 2005.
  3. 3. Tjønnfjord GE, Holme PA. Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors. Vascular Health and Risk Management. 2007:3(4):527-531.
  4. 4. World Federation of Hemophilia. Suggestions for the management of factor VIII inhibitors. 2000.
  5. 5. Turecek PL, Varadi K, Gritsch H, Schwarz HP. FEIBA: mode of action. Haemophilia. 2004: 10 (2): 3-9.
  6. 6. Varadi K, Négrier C, Berntorp E, Astermark J, Bordet JC, Morfini M, et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. Journal of Thrombosis and Haemostasis. 2003: 1: 2374-2380.
  7. 7. Hilgartner MW, Knatterud GL. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in haemophiliacs with inhibitors. Blood. 1983:61:36-40.
  8. 8. Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109(2):546-551.
  9. 9. Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia. 2007:1-7.
  10. 10. DiMichele D, Négrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia. 2006;12:352-362.
  11. 11. Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia. 2009;15(1):3-10.
  12. 12. Teitel J, Berntorp E, Collins P, D'Oiron R, Ewenstein B, Gomperts E, et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia. 2007:13:256-263.
  13. 13. US National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) Recommendation Regarding the Use of Bypassing Agents in Patients with Hemophilia A or B and Inhibitors. MASAC Document #167. 2006.
  14. 14. Luu H, Ewenstein B. FEIBA safety profile in multiple modes of clinical and home-therapy application. Haemophilia. 2004:10(Suppl. 2):10-16

Rapid onset and sustained activity

FEIBA stops bleeds quickly and offers a long dosing interval. Read more

Proven efficacy

Discover the efficacy of FEIBA in both on-demand and prophylaxis treatment. Read more

Integral to inhibitor management

Learn how FEIBA is integral to the management of patients with inhibitors. Read more